Viva Biotech proposes dollar-denominated convertible bond offering

By Abigail W. Adams

Portland, Me., Jan. 22 – Viva Biotech Holdings has proposed an offering of dollar-denominated convertible bonds, according to a company announcement.

JPMorgan has been appointed as global coordinator and JPMorgan, HSBC and CICC joint bookrunners for the proposed Regulation S offering.

The completion of the offering is subject to market conditions and investor interest.

Viva Biotech is a Shanghai-based drug discovery service provider.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.